Table 2.
Treatment Retention and Primary Outcomes by Group for the 127 Subjects in the Intention-to-Treat Sample*
| Outcome Variables | Treatment Condition†
|
CM Contrast‡
|
SO Contrast‡
|
||||
|---|---|---|---|---|---|---|---|
| Standard Naltrexone (n = 44) | CM (n = 35) | SO + CM (n = 48) | t | P | t | P | |
| Primary | |||||||
| No. of weeks in treatment | 5.6 (4.5) | 7.4 (4.4) | 7.4 (5.1) | 2.0 | .05 | 0.1 | .96 |
| No. of naltrexone doses | 14.2 (12.4) | 17.8 (13.4) | 19.4 (15.4) | 1.9 | .06 | 0.2 | .83 |
| No. of drug-free urine specimens during treatment | 8.9 (12.0) | 13.6 (13.6) | 16.7 (15.1) | 2.3 | .02 | 0.9 | .35 |
| Secondary | |||||||
| No. of opiate-free urine specimens | 13.5 (12.0) | 18.9 (13.7) | 20.2 (15.5) | 2.1 | .04 | 0.7 | .48 |
| No. of cocaine-free urine specimens | 12.2 (12.6) | 16.0 (13.5) | 18.5 (15.0) | 1.9 | .06 | 0.8 | .44 |
| Drug-free urine specimens, % | 45.2 (39.3) | 57.4 (39.1) | 59.7 (39.7) | 1.8 | .08 | 0.3 | .77 |
| Maximum consecutive abstinence, d | |||||||
| Opioids | 37.7 (32.8) | 49.1 (32.7) | 53.4 (36.5) | 2.0 | .05 | 0.5 | .60 |
| Cocaine | 37.1 (32.4) | 45.0 (32.3) | 51.7 (35.4) | 1.7 | .09 | 0.9 | .39 |
| Days abstinent, % | |||||||
| Opioids | 79.8 (25.5) | 87.5 (20.9) | 89.0 (20.3) | 1.9 | .06 | 0.3 | .77 |
| Cocaine | 82.6 (23.0) | 84.3 (24.5) | 88.6 (14.9) | 0.9 | .34 | 0.9 | .37 |
*
Data are the results of an analysis of variance. df = 2,124. Abbreviations are explained in the first footnote to Table 1.
†
Data are given as adjusted mean (SE). Treatment groups are explained in the second footnote to Table 1.
‡
The CM and SO contrasts are described in the “Data Analyses” subsection of the “Subjects and Methods” section.